Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases

(2017) Ashlyn S. Everett et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Granuloma annulare associated with immune checkpoint inhibitors

(2017) J. Wu et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

(2017) Georgina V Long et al.   LANCET ONCOLOGY

Interstitial granulomatous dermatitis during talimogen laherparepvec treatment

(2017) Anna L. Frauchiger et al.   MELANOMA RESEARCH

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

(2016) George Jour et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

(2016) Jonathan L. Curry et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Interstitial granulomatous drug reaction induced by quetiapine

(2015) E. S.-T. Tan et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors

(2015) C Ciccarese et al.   Expert Opinion on Drug Metabolism & Toxicology

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis

(2015) Omar Abdel-Rahman et al.   Future Oncology

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial granulomatous drug reaction due to febuxostat

(2014) Atzori Laura et al.   Indian Journal of Dermatology Venereology & Leprology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial granulomatous dermatitis with arthritis associated with trastuzumab

(2009) G Martín et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY